medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-6-88-92medsovet-1891Research ArticleПоддерживающая терапия в онкологииSupportive care in oncologyПРОФИЛАКТИКА ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ В ГРУППАХ ВЫСОКОГО РИСКАPREVENTION OF THROMBOTHIC COMPLICATIONS IN CANCER PATIENTS IN HIGH-RISK GROUPSПТУШКИНВ. В.PTUSHKINV. V.

д.м.н., профессор

MD, Prof.

ГКБ им. С.П. Боткина ДЗ г. МосквыRussian Federation201719062017068892Copyright © ПТУШКИН В.В., 20172017ПТУШКИН В.В.PTUSHKIN V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1891

Венозные тромбозы/тромбоэмболии (ВТЭ) являются частым осложнением и признаются одной из основных причин смертности у пациентов с опухолями. Обычно у онкологических больных имеется несколько факторов риска развития венозного тромбоза, в том числе операция, иммобилизация, наличие центрального катетера, химиотерапия. Эффективная профилактика и лечение ВТЭ снижают уровень заболеваемости и смертности, а также улучшают качество жизни онкологических больных. Низкомолекулярные гепарины (НМГ) являются эффективными и безопасными средствами для профилактики и лечения ВТЭ при раке.

Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, chemotherapy. Effective prophylaxis and treatment of VTE reduced morbidity and mortality, and improved quality of life. Low-molecular-weight heparin (LMWH) is preferred as an effective and safe means for prophylaxis and treatment of VTE.

онкологиятромбозыпрофилактиканизкомолекулярные гепариныбемипаринoncologythrombosisprophylaxislow molecular weight heparinsbemiparinReferencesShen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J, 1980, 73: 841-843.Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J, 1980, 73: 841-843.Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost, 2003, 29: 247-583.Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost, 2003, 29: 247-583.Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med, 1981, 24: 23-35.Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med, 1981, 24: 23-35.Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry, 1985, 24: 5558-5567.Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry, 1985, 24: 5558-5567.Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcomebased prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg, 2006, 243(1): 89-9545.Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcomebased prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg, 2006, 243(1): 89-9545.Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost, 1997, 78: 141-4.Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost, 1997, 78: 141-4.Levitan N, Dowlati A, Remick S et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine, 1999, 78: 285-91.Levitan N, Dowlati A, Remick S et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine, 1999, 78: 285-91.Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med, 2004, 164(15): 1653-61.Elting LS, Escalante CP, Cooksley C, Avritscher EB, Kurtin D, Hamblin L, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med, 2004, 164(15): 1653-61.Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy, 2009, 29(8): 943-53.Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy, 2009, 29(8): 943-53.Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest, 1995, 108: 978-981.Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest, 1995, 108: 978-981.Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or lowmolecular- weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost, 2000, 83: 14-19.Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or lowmolecular- weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost, 2000, 83: 14-19.Leizorovicz, A, Cohen, AT, Turpie, AGG, et al A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study [abstract]. J Thromb Haemost, 2003, 1(suppl): OC396.Leizorovicz, A, Cohen, AT, Turpie, AGG, et al A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study [abstract]. J Thromb Haemost, 2003, 1(suppl): OC396.Cohen, AT, Davidson, BL, Gallus, AS, et al Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ, 2006, 332(7537): 325-9.Cohen, AT, Davidson, BL, Gallus, AS, et al Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ, 2006, 332(7537): 325-9.Huber O, Bounameux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg, 1992, 127: 310-313.Huber O, Bounameux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. Arch Surg, 1992, 127: 310-313.Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T: Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost, 2003 May, 1(5): 971-5.Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T: Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost, 2003 May, 1(5): 971-5.Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev, 2002, 28: 141-4.Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev, 2002, 28: 141-4.Bergqvist D, Agnelli G, Cohen AT et al Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med, 2002, 346: 975- 980.Bergqvist D, Agnelli G, Cohen AT et al Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med, 2002, 346: 975- 980.Kakkar VV, Balibrea J, Martinez-Gozalez LJ et.al. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. Journal of Thrombosis and Haemostasis, 2010, 8: 1223-1229.Kakkar VV, Balibrea J, Martinez-Gozalez LJ et.al. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. Journal of Thrombosis and Haemostasis, 2010, 8: 1223-1229.Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 1994, 343(8902): 886-9.Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 1994, 343(8902): 886-9.Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double- blind study. Lancet Oncol, 2009, 10(10): 943-9.Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double- blind study. Lancet Oncol, 2009, 10(10): 943-9.Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Lowmolecular- weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost, 2012, 18(2): 159-65.Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Lowmolecular- weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost, 2012, 18(2): 159-65.Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med, 2012, 366(7): 601-9.Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med, 2012, 366(7): 601-9.Coughlin RS. Thrombin signaling and proteaseactivated receptors. Nature, 2000, 407: 258-264.Coughlin RS. Thrombin signaling and proteaseactivated receptors. Nature, 2000, 407: 258-264.Maragoudakis, ME, Tsopanoglou, NE, Andrio poulou, P Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans, 2002, 30: 173-177.Maragoudakis, ME, Tsopanoglou, NE, Andrio poulou, P Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans, 2002, 30: 173-177.Wang A, Templeton DM. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int, 1996, 49(2): 437-48.Wang A, Templeton DM. Inhibition of mitogenesis and c-fos induction in mesangial cells by heparin and heparan sulfates. Kidney Int, 1996, 49(2): 437-48.Collen A, Koolwijk P, Kroon ME, van Hinsbergh VWM. The influence of fibrin structure on the formation and maintenance of capillary-like tubules. Angiogenesis, 1998, 2: 153-165.Collen A, Koolwijk P, Kroon ME, van Hinsbergh VWM. The influence of fibrin structure on the formation and maintenance of capillary-like tubules. Angiogenesis, 1998, 2: 153-165.Lee AE, Rogers LA, Jeffery RE and Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis, 1988, 6: 463-471.Lee AE, Rogers LA, Jeffery RE and Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis, 1988, 6: 463-471.Massuti B, Lecumberri R, Lopez GM et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited- stage small cell lung cancer (SCLC) – Final results. J Clin Oncol, 2012, 30(suppl): abstr 7095.Massuti B, Lecumberri R, Lopez GM et al. ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited- stage small cell lung cancer (SCLC) – Final results. J Clin Oncol, 2012, 30(suppl): abstr 7095.Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2_suppl).Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2_suppl).

The authors declare that there are no conflicts of interest present.